Drug intelligence / Profile preview

FIG-003

Development stage: Preclinical
Lead developer: Fig Therapeutics
Modality: Gene Therapies
Administration: Intratumoral

Overview

FIG-003 is a preclinical gene therapy candidate developed by Fig Therapeutics for the treatment of HER2-overexpressing tumors, such as HER2-positive breast cancer. The therapeutic utilizes the company's proprietary Symphony platform, which employs a helper-dependent adenovirus (HD-Ad) viral vector to deliver targeted payloads directly to tumor cells. By leveraging the high capacity and reduced immunogenicity of HD-Ad vectors, FIG-003 is designed to provide potent, localized expression of anti-tumor agents while minimizing systemic toxicity. The program is currently in the discovery phase of development.

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on FIG-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FIG-003.

Explore the full profile